Physician profile
David Miller
NPI 1740273622
$2,038.03
in general payments reported to CMS, 2019-2025
13 companies · $217 in 2025
The $217 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2020: $156 · 2021: $172 · 2022: $123 · 2023: $306 · 2024: $302 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $824.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $532.96 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $515.45 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.03 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $227.17 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $126.78 | 2020-2025 | |
| Amgen INC. | $69.56 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $68.95 | 2019 | |
| Merck Sharp & Dohme LLC | $62.24 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $48.07 | 2019 | |
| Antares Pharma, INC. | $22.53 | 2023 | Tlando, Xyosted, Nocdurna |
| Glaxosmithkline, LLC. | $21.20 | 2023 | Trelegy Ellipta |
| Acella Pharmaceuticals, LLC | $20.54 | 2025 | NP Thyroid 60 |
| Astellas Pharma US INC | $18.55 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.